0001140361-23-000721.txt : 20230105
0001140361-23-000721.hdr.sgml : 20230105
20230105194430
ACCESSION NUMBER: 0001140361-23-000721
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230103
FILED AS OF DATE: 20230105
DATE AS OF CHANGE: 20230105
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Coulie Bernard
CENTRAL INDEX KEY: 0001808895
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39303
FILM NUMBER: 23513201
MAIL ADDRESS:
STREET 1: C/O PLIANT THERAPEUTICS, INC.
STREET 2: 260 LITTLEFIELD AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PLIANT THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001746473
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 474272481
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 260 LITTLEFIELD AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-481-6770
MAIL ADDRESS:
STREET 1: 260 LITTLEFIELD AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
form4.xml
X0306
4
2023-01-03
0001746473
PLIANT THERAPEUTICS, INC.
PLRX
0001808895
Coulie Bernard
C/O PLIANT THERAPEUTICS, INC.
260 LITTLEFIELD AVENUE
SOUTH SAN FRANCISCO
CA
94080
true
true
President and CEO
Common Stock
2023-01-03
4
M
0
15000
2.08
A
108812
D
Common Stock
2023-01-03
4
S
0
15000
19.3301
D
93812
D
Common Stock
2023-01-04
4
M
0
15000
2.08
A
108812
D
Common Stock
2023-01-04
4
S
0
15000
19.0627
D
93812
D
Common Stock
449317
I
See footnote
Stock Option (right to buy)
2.08
2023-01-03
4
M
0
15000
0
D
2029-01-23
Common Stock
15000
282380
D
Stock Option (right to buy)
2.08
2023-01-04
4
M
0
15000
0
D
2029-01-23
Common Stock
15000
267380
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $19.80, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $19.185, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
Shares held by The Coulie/Leyman Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
1/48th of the shares subject to the original option grant vest and become exercisable in substantially equal installments on each monthly anniversary of January 24, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date.
/s/ Mike Ouimette, attorney-in-fact
2023-01-05